Plus Therapeutics Reports Improved Q1 Net Loss, $15M Capital Raise, and Key Progress on REYOBIQ & CNSide Programs

summarizeSummary

Plus Therapeutics announced improved Q1 financial results, a $15 million capital raise, and significant commercialization progress for its REYOBIQ and CNSide platforms, bolstering its financial stability and product pipeline.

check_boxKey Events

• Improved Q1 Financials

  Net loss significantly reduced to $6.9 million in Q1 2026 from $17.4 million in Q1 2025 (post-reverse split), indicating improved financial performance.

• Strengthened Cash Position

  Cash and investments increased to $15.1 million as of March 31, 2026, driven by a $15 million public offering completed in January 2026, providing crucial capital runway.

• REYOBIQ Commercialization Progress

  Secured an AMA Category III CPT reimbursement code for convection-enhanced delivery with REYOBIQ and added a second GMP manufacturing site, advancing commercial readiness.

• CNSide Payer Coverage Expansion

  Expanded U.S. payer coverage to approximately 81 million covered lives, including a new agreement with Blue Shield of California, and successfully enrolled with Medicare.

auto_awesomeAnalysis

This 8-K, filed concurrently with the Q1 2026 10-Q, highlights significant financial improvements and operational advancements. The company reported a substantially reduced net loss and a strengthened cash position following a $15 million public offering. Key progress includes securing a CPT reimbursement code for its REYOBIQ therapy and expanding payer coverage for its CNSide diagnostic platform, which are crucial steps for commercialization and revenue growth. These updates are critical for a company that previously raised "substantial doubt about its ability to continue."